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Abstract
Background: Onabotulinumtoxin A (OnabotA) injection has been investigated as a novel treatment for benign
prostatic enlargement caused by benign prostatic hyperplasia. An OnabotA - induced volume reduction caused by
sympathetic fibers impairment has been proposed as a potential mechanism of action. Our aim was to investigate
the expression of apoptosis-regulating proteins in the rat prostate following OnabotA intraprostatic injection.
Methods: Adult Wistar rats were injected in the ventral lobes of the prostate with 10 U of OnabotA or saline. A set
of OnabotA-injected animals was further treated with 0.5 mg/kg of phenylephrine (PHE) subcutaneously daily. All
animals were sacrificed after 1 week and had their prostates harvested. Immunohistochemical staining was
performed for Bax, Bcl-xL and caspase-3 proteins and visualized by the avidin-biotin method. The optical density of
the glandular cells was also determined, with measurement of differences between average optical densities for
each group.
Results: Saline-treated animals showed intense epithelial staining for Bcl-xL and a faint labelling for both Bax and
Caspase-3. OnabotA-treated rats showed a reduced epithelial staining of Bcl-xL and a consistently increased Bax
and Caspase-3 staining when compared with saline-treated animals. PHE-treated animals showed a stronger Bcl-xL
staining and reduced staining of both Bax and Caspase-3 when compared to the OnabotA group. Mean signal
intensity measurements for each immunoreaction confirmed a significant decrease of the signal intensity for Bcl-xL
and a significant increase of the signal intensity for Bax and Caspase 3 in OnabotA-injected animals when
compared with the control group. In OnabotA+PHE treated animals mean signal intensity for Bcl-xL, Bax and
Caspase 3 immunoreactions was identical to that of the control animals.
Conclusions: These results support the hypothesis that OnabotA activates apoptotic pathways in the rat prostate
through a mechanism that involves sympathetic outflow impairment.
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Background
Botulinum toxin type A (BoNT/A) is one of seven sero-
types of a neurotoxin produced by Clostridium botuli-
num. The toxin binds synaptic vesicle type 2 (SV2)
expressed on the neuronal surface at points where
synaptic vesicles fuse with the cytoplasmatic membrane.
When synaptic vesicles are recycled, the neurotoxin,
attached to SV2, is internalized and later cleaved into a
light and heavy chain. The former is responsible for the
inactivation of SNAP25 (synaptosome-associated protein
of 25 kDa), a membrane protein which is crucial for the
fusion of the synaptic vesicles with the neuronal mem-
brane and subsequent release of neurotransmitters [1].
Despite its high toxicity it has several clinical applica-
tions, being approved by the US Food and Drug Admin-
istration (FDA) for treatment of blepharospasm,
strabism, striated muscle dystonias and primary axillary
hyperhidrosis. In addition, BoNT/A is being investigated
off-label in a multitude of other diseases, including
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benign prostatic enlargement (BPE) caused by benign
prostatic hyperplasia (BPH).
BoNT/A has been shown to consistently reduce the
volume of the prostate in the rat [2] and in the dog [3].
A 30 to 50% reduction in prostate volume was also
observed in several human trials in which BoNT/A was
injected in moderate-to-large volume glands [4,5],
although in a large phase 2 clinical trial, neither the
prostate volume nor the serum PSA showed any signifi-
cant decrease following the neurotoxin injection [6].
Nevertheless, it has been repeatedly demonstrated that
BoNT/A induces apoptosis in rat and dog prostates, as
shown by a positive deoxynucleotidyl transferase biotin-
dUTP nick-end labelling (TUNEL) [2,3,7,8]. A positive
TUNEL staining was also reported in one study which
used prostate samples obtained from two patients fol-
lowing BoNT/A administration [9]. Interestingly, subcu-
taneous injection of the sympathicomimetic agent
phenylephrine (PHE) in BoNT/A-injected rats seems to
attenuate the TUNEL reaction [8], suggesting that the
sympathetic nervous system could play an important
role in the mechanisms of cell survival in the prostate
gland, as previously forwarded by McVary and collea-
gues [10].
TUNEL reaction specifically labels nuclei following
DNA fragmentation [11]. However, the activation of the
apoptotic cascade in the prostate preceding DNA frag-
mentation was never investigated. Among the apoptosis
regulating proteins which have been studied in the pros-
tate are Caspase-3 and the proteins from the Bcl-2
family. The BCL-2 proto-oncogene family function has
been postulated as one of the critical mechanisms for
determining cell death, having a pivotal role in the regu-
lation of the mitochondrial apoptosis pathway [12].
BCL-2 family members are divided into those that pro-
tect the cell from apoptosis, such as Bcl-2 and Bcl-xL,
and those that induce apoptosis, such as Bax [12,13].
Bcl-2 and Bcl-xL overexpression in mammalian cells
results in delayed apoptosis [12-15]. Bax inhibits Bcl-2
function and allows the cell to enter the death program
[12]. Caspase-3 is a member of the caspase family of
cysteine proteases which is central to the cell death
pathway, as the extrinsic and intrinsic cell death path-
ways converge to activate this protein for the final
execution of apoptosis [14]. Activation of caspase-3 is
primarily responsible for the cleavage of poly (adenosine
diphosphate-ribose) polymerase (PARP). It has been
suggested that PARP contributes to cell death by deplet-
ing the cell of nicotinamide adenine dinucleotide and
adenosine triphosphate [13].
In the present study, which constitutes an extension of
a previous work from our group [8], we tried to further
clarify the prostate cell apoptosis mechanisms induced
by OnabotA by exploring changes in the expression of
apoptosis-regulating proteins in the rat prostate after
local administration of the neurotoxin.
Methods
This study is an extension from a previous work pub-
lished by our group [8]. Briefly, adult male Wistar rats
(Charles River Laboratories, Barcelona, Spain) weighing
300-350 g were maintained in an animal house at 22°C,
60% humidity, under a dark-light cycle of 12 hours.
Onabotulinumtoxin A (OnabotA, BOTOX®) was
obtained from Allergan (Irvine, CA, USA). Phenylephr-
ine (PHE) was supplied by ICMA (Portugal). All the
experiments were performed in accordance with the
revised US National Institutes of Health (NIH) Guide
for the Care and Use of Laboratory Animals and with
the European Communities Council Directive (86/609/
EEC). The use of animals was approved by the animal
subjects review board of the University of Porto, Porto,
Portugal. Furthermore, all efforts were made to mini-
mize the number of animals used.
Rats were anaesthetised with isoflurane (5% for induc-
tion and 2% for maintenance); a lower abdominal inci-
sion was performed, and the prostate was exposed and
separated from the surrounding tissue. Saline (0.2 ml, n
= 6) or 10 U of OnabotA in 0.2 ml of saline (n = 18)
were slowly injected in several points of the ventral
lobes of the prostates using a 30-gauge needle, as pre-
viously described [8]. Care was taken to administer 0.1
ml in each lobe. Six of the rats injected with OnabotA
were further treated with 0.5 mg/kg of PHE subcuta-
neously daily. Experimental time course and OnabotA
and PHE doses were chosen according to preliminary
data, as stated in our previous work [8].
All animals were sacrificed after 1 week. Prostates
were harvested and surrounding tissues and fat were
carefully removed. The entire prostates were immer-
sion-fixed in 4% paraformaldehyde and cut in 20 μm
transverse sections using a Microm cryostat.
In the present work, prostate tissue samples from each
animal were immunoreacted against the active form of
Caspase-3 (ab13847, Abcam, Cambridge, UK; diluted to
1:500), Bcl-xL (#2762, Cell Signaling Technology; diluted
to 1:100) and Bax (ab6943, Abcam, Cambridge, UK;
diluted to 1:1000), all raised in rabbit. Immunoreactions
were performed on batches for each antigen. After
thawing, sections were washed and inhibition of endo-
genous peroxidase was obtained by incubation with 10
ml of 50% ethanol containing 0.3% H2O2. Sections were
incubated with sodium borohydrate 1% for 30 m,
blocked and further incubated in primary antibodies for
48 h at 4°C (Caspase-3, Bcl-xL and Bax). Sections were
then incubated with a swine anti-rabbit biotinylated sec-
ondary antibody and avidin-biotin-HRP complex (ABC-
Vector Laboratories, Burlingame, California). The
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reaction was revealed using diaminobenzidine (DAB).
An omission of the primary antibody was used as nega-
tive control.
The optical density of the cytoplasm of the glandular
cells following immunohistochemical reactions to Cas-
pase-3, Bcl-xL and Bax was determined in controls and
treated animals on an arbitrary scale between 0 (white
pixels) and 255 (black pixels), with the Image J 1.38×
software (NIH, USA) using 6 random images taken by a
Zeiss microscope attached to a Zeiss Axiocam MRc5
camera. Then, the average optical density of each gland
was calculated and differences between groups were
analyzed using Kruskal-Wallis test followed by Dunn’s
Multiple Comparisons Test (GraphPad InStat, version
3.00).
Results
Saline-injected animals showed intense epithelial stain-
ing for Bcl-xL (A1) and a faint labelling for both
Caspase-3 (B1) and Bax (C1), both in glands with tall
(Figure 1) and short epithelial lining (Figure 2).
OnabotA-injected rats showed a reduced epithelial
staining of Bcl-xL (A2) when compared with saline-trea-
ted animals in tall and short epithelial cells. The same
animals showed a consistently increased Caspase-3 (B2)
and Bax (C2) staining of epithelial cells (Figure 1 and 2).
PHE-treated animals showed a stronger Bcl-xL (A3)
staining and reduced staining of both Caspase-3 (B3)
and Bax (C3), when compared to the OnabotA group
(Figure 1 and 2).
Mean signal intensity measurements for each immu-
noreaction confirmed a significant decrease of the signal
intensity for Bcl-xL and a significant increase of the sig-
nal intensity of Caspase 3 and Bax immunoreactions in
OnabotA-injected animals when compared with control
groups. In OnabotA+PHE treated animals, mean signal
intensity for Bcl-xL, Caspase 3 and Bax immunoreac-
tions was identical to that of control groups (Figure 3).
Figure 1 immunohistochemical expression of Bcl-xL (A), Caspase-3 (B) and Bax (C) in glands with tall epithelial lining in the control
group (1), OnaBotA group (2) and OnaBotA+PHE group (3). Scale bar indicates 100 μm.
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Discussion
Our previous study [8], in accordance with other works
[2,3,7,9], had shown the occurrence of prostate apopto-
sis following OnabotA. As previously mentioned, in rats
injected with the toxin, prostate weight significantly
decreased and there was a positive TUNEL reaction in
all animals [8].
The present study further confirms the activation of
the apoptotic pathway, by showing an increased expres-
sion of proapoptotic proteins and decreased expression
of antiapoptotic proteins following OnabotA injection.
BoNT/A is a nonspecific neurotoxin. In fact, BoNT/A
is able to impair all types of neurons that express SV2
protein on its surface and require SNAP25 protein for
synaptic vesicle fusion [16]. In the prostate, cholinergic
and adrenergic nerves are the most numerous. Choliner-
gic nerves are found mainly around acinar structures
and their outflow seems to be essential for glandular
secretion [17]. Adrenergic fibers are more prevalent in
the stroma [17]. Sensory fibers are scarce in the prostate
tissue, being restricted to the suburethral tissue and eja-
culatory ducts [18]. In our previous study, we had
observed that BoNT/A-injected animals subsequently
treated with a subcutaneous injection of the sympathico-
mimetic agent PHE exhibited a decreased number of
TUNEL-positive cells when compared with the BoNT/A
group. In contrast, the replacement of the cholinergic
outflow after BoNT/A administration with a cholinergic
agonist (betanecol) could not prevent BoNT/A-induced
TUNEL reaction. Our present study also confirms the
important role of the sympathetic innervation for the
prostate regulation in the rat. In fact, systemic PHE
administration after BoNT/A injection in the gland,
which is expected to replace the normal neuronal sym-
pathetic drive impaired by the neurotoxin, prevented the
overexpression of the proapoptotic proteins Bax and
Caspase-3, therefore explaining why these tissues had an
absent TUNEL reaction [8].
Figure 2 immunohistochemical expression of Bcl-xL (A), Caspase-3 (B) and Bax (C) in glands with short epithelial lining in the control
group (1), OnaBotA group (2) and OnaBotA + PHE group (3). Scale bar indicates 100 μm.
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The association between the sympathetic nervous sys-
tem and prostate regulation is not new. Denervation of
the rat prostate achieved by bilateral pelvic ganglion
denervation was shown to cause the loss of structural
and functional integrity, with lower prostatic weight,
decreased cell height, and reduced secretory activity
[19]. Moreover, ipsilateral decreases in ventral prostate
weight, DNA, and protein content were found after
Figure 3 mean signal intensity measurements for Bcl-xL, Caspase 3 and Bax in control, OnabotA and OnabotA + PHE groups (*
indicates p < 0.05; ** indicates p < 0.01; *** indicates p < 0.001).
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selective unilateral sympathectomy [10]. Spontaneous
hypertensive rats which exhibit an increased sympathetic
drive show a more exuberant glandular epithelium than
controls [20]. In humans, prolonged administration of
the alpha blockers doxazosin or terazosin to BPH
patients was shown to induce epithelial and stromal cell
apoptosis [21], although insufficient to cause a reduction
in prostate volume [22]. In another human trial, an
association was found between AUA symptom score,
BPH impact index score, quality of life score and
changes in systolic and sympathetic overactivity as
determined by the tilt test [23]. Additionally, prostate
transition zone volume was found to be independently
associated with the plasma norepinephrine response to
tilt [23]. Ullrich and colleagues found that an excess of
physiological activity to standardized stressors correlate
to transitional zone volume, total prostate gland volume,
and more severe LUTS [24].
Similarly to studies in rodents, experiments using
higher mammals have shown that neurotoxin injection
caused profound changes in the prostate. In the dog
prostate, the animal which bears more resemblance with
the human gland, Lin and coworkers found that BoNT/
A administration caused intense vacuolization in the
cytoplasm of fibroblasts and smooth muscle cells [25].
In several human studies, OnabotA injection was fol-
lowed by a reduction in prostate volume [3-5,9,26-29].
It should, however, be stated that such a reduction was
not found in a recent large study comparing the effect
of intraprostatic injection of different doses of OnabotA
[6]. In accordance with this discrepancy, a PSA decrease
reported by some studies was not confirmed by other
groups [6,9]. Future studies are needed to clarify these
discrepancies.
Apoptosis may play a central role both in the develop-
ment and self-renewal of normal prostate and in the
etiology of BPH. Shariat and colleagues [12] found an
increase in the expression of survivin and Bcl-2, two
antiapoptotic genes, in epithelial and stromal cells in
BPH. Bcl-2 overexpression was detected in the majority
of the BPH samples in a study by Zhang and colleagues
which included 60 patients with histologically deter-
mined BPH. The authors concluded that the develop-
ment of BPH may be associated with both stromal
growth due to active stromal cell proliferation and
epithelial growth due to reduced glandular apoptosis
[14].
Whether these findings will contribute to the future
application of BoNT/A for the treatment of BPH/
LUTS is unknown. Clearly they offer a robust rational
support for its use. Prostate volume reduction could
reduce the static component of BPH-related bladder
outlet obstruction in a manner similar to 5-alpha-
reductase inhibitor drugs [30]. In addition, the
impairment of the sympathetic system is also expected
to reduce the dynamic component of BPH [3,25].
However, the clinical application of BoNT/A in BPH
will be dependent upon the results coming from ran-
domized clinical trials. Until now, the positive effects
were seen in case series which are insufficient to draw
any definitive conclusions.
Conclusions
These results support the hypothesis that BoNT/A acti-
vates apoptotic pathways in the rat prostate through a
mechanism that involves sympathetic outflow impair-
ment. However, the scarcity of stromal component in
the rat prostate precluded a thorough evaluation of the
neurotoxin in the non-glandular tissue. Therefore,
further studies need to be carried out in order to inves-
tigate the effect of the neurotoxin in the several cellular
components of the prostate.
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